Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + trastuzumab + aromatase inhibitor
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy regimen consisting of pyrotinib, trastuzumab, and an aromatase inhibitor (AI). Pyrotinib is an oral, irreversible pan-HER tyrosine kinase inhibitor (TKI) that targets EGFR (HER1), HER2, and HER4. Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). Aromatase inhibitors (such as letrozole, anastrozole, or exemestane) are endocrine therapies that block the enzyme aromatase, thereby reducing estrogen production. This triplet combination is being investigated by the Tianjin Medical University Cancer Institute and Hospital as a neoadjuvant (preoperative) treatment for patients with stage II-IIIA hormone receptor-positive (HR+) and HER2-positive breast cancer, aiming to achieve synergistic anti-tumor effects through simultaneous dual HER2 blockade and estrogen deprivation.
- Other names
- pyrotinib + trastuzumab + AIpyrrolitinib + trastuzumab + AI
02
Targets
CYP19A1 (Aromatase)PDGFRB (Platelet-derived growth factor receptor beta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)KIT (c-KIT proto-oncogene receptor tyrosine kinase)AR (Adrenergic receptors)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on pyrotinib + trastuzumab + aromatase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + trastuzumab + aromatase inhibitor.